According to a recent LinkedIn post from Truveta, the terminology for PCOS is evolving toward Polyendocrine Metabolic Ovarian Syndrome, or PMOS, reflecting a broader hormonal and metabolic profile. The post notes that this reframing encompasses links to weight, insulin resistance, reproductive health, dermatologic issues, and mental health impacts.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights an internal analysis of real-world data showing GLP-1 prescriptions, specifically semaglutide and tirzepatide, rising among women previously described as having PCOS. According to the post, prescribing rates for these drugs in this population increased from 2.4% in 2021 to 17.6% in 2025, indicating more than a seven-fold rise over the period.
The post suggests that Truveta is positioning its data platform as a tool for tracking changing care patterns in complex metabolic conditions. For investors, this emphasis on GLP-1 utilization and evolving disease definitions may underscore the relevance of Truveta’s real-world evidence capabilities to pharmaceutical partners, payers, and health systems focused on obesity, endocrinology, and women’s health.
If Truveta can deepen its role in analyzing adoption trends of high-value therapies such as GLP-1 agonists, it could strengthen its competitive position in the real-world data and evidence market. This could, in turn, support revenue opportunities tied to research collaborations, outcomes studies, and commercialization analytics for therapies addressing metabolic and reproductive disorders.